Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Irinotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 6/20 | 0.77 |
| ▸ | GLA | P06280 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.99 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.99 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.99 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.99 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.99 |
| ▸ | MMP1 | P03956 | 1/20 | 0.99 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.99 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.99 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.99 |
| ▸ | ACHE | P22303 | 1/20 | 0.99 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Irinotecan SCHEMBL4450369 | 1.00 | GLA (1.00) | GLAGAAKDM4EALDH1A1LMNA | |
| Irinotecan SCHEMBL663859 | 1.00 | GLA (1.00) | GLAGAAKDM4EALDH1A1LMNA | |
| Irinotecan SCHEMBL29363805 | 1.00 | GLA (1.00) | GLAGAAKDM4EALDH1A1LMNA | |
| Irinotecan SCHEMBL4033 | 1.00 | GLA (1.00) | GLAGAAKDM4EALDH1A1LMNA | |
| Irinotecan SCHEMBL359364 | 0.99 | PAX8 (1.00) | GLAGAAKDM4EALDH1A1LMNA | |
| Irinotecan SCHEMBL572716 | 0.99 | PAX8 (1.00) | GLAGAAKDM4EALDH1A1LMNA | |
| Irinotecan SCHEMBL30822976 | 0.99 | PAX8 (1.00) | GLAGAAKDM4EALDH1A1LMNA | |
| Irinotecan SCHEMBL29359605 | 0.99 | PAX8 (1.00) | GLAGAAKDM4EALDH1A1LMNA | |
| Irinotecan SCHEMBL12313065 | 0.99 | GLA (1.00) | GLAGAAKDM4EALDH1A1LMNA | |
| Irinotecan SCHEMBL131381 | 0.99 | GLA (1.00) | GLAGAAKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190256608-A1 | COMBINATION TREATMENTS AND USES AND METHODS THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-22 | — | — | US | disclosed |
| US-20180222989-A1 | COMBINATION TREATMENTS AND USES AND METHODS THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-08-09 | — | — | US | disclosed |
| US-20170239274-A1 | COMBINATION | NOVARTIS PHARMA AG (CH) | 2017-08-24 | — | — | US | disclosed |
| US-20150045405-A1 | CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride | NOVARTIS AG (CH) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239274-A1 | COMBINATION | CYP17A1, HSD17B11, HSD17B1 | TOP1 280/4885GLA 2274/4885GAA 698/4885 |
| US-20190256608-A1 | COMBINATION TREATMENTS AND USES AND METHODS THEREOF | CD274, PDCD10, PDCD1LG2 | TOP1 1185/4885GLA 2980/4885GAA 3330/4885 |
| US-20150045405-A1 | CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride | PIK3CD, PIK3CA, PIK3CB | TOP1 919/4885GLA 2438/4885GAA 1559/4885 |
| US-20180222989-A1 | COMBINATION TREATMENTS AND USES AND METHODS THEREOF | CD274, PDCD1LG2, PDCD1 | TOP1 794/4885GLA 2760/4885GAA 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.